Evidence map›Paper›PMID 40715618›Full record

ArticleInvestigational new drugs2025

Clinical features, treatment and outcomes of dabrafenib-associated uveitis.

Jieqiong Liu, Wei Sun, Chunjiang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Rates of Drug-Induced Uveitis: A Review by Medication Class.Clinical ophthalmology (Auckland, N.Z.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jieqiong LiuDepartment of Hematology and Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, 410005, Hunan, China.
Wei SunDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Chunjiang WangCollege of Pharmacy, Changsha Medical University, Changsha, 410219, Hunan, China. wongcj@csu.edu.cn.

Funding

Hunan Provincial Natural Science Foundation of China 2025JJ80494
6 · The paper itself

Abstract

backgroundTo explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.

methodsThe database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.

resultsTwenty-six patients were included in the study, with a median age of 56 years (range 30, 75). The onset time of uveitis was 3 months (range 0.75, 96) after administration. The types of uveitis were pan-uveitis (38.5%), anterior uveitis (34.6%), posterior uveitis (15.4%), and intermediate uveitis (3.8%). Fifty percent of the patients were Vogt-Koyanagi-Harada disease-like uveitis. After discontinuation of dabrafenib and treatment with topical and systemic steroids, the symptoms of uveitis improved in all patients.

conclusionPatients are advised to have regular ophthalmology examinations during the use of dabrafenib. Timely administration of systemic or local corticosteroid treatment can significantly improve the symptoms of patients.

Indexed as

Antineoplastic AgentsImidazolesOximesUveitisAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntineoplastic AgentsdabrafenibImidazolesOximesBRAF inhibitorDabrafenibOcular toxicityUveitisVKH-like uveitis

Identifiers

PMID40715618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.